The goal of this study is to determine if an investigational oral medication is safe and effective. This treatment with the investigational oral medication is compared to treatment with a placebo. A placebo is an inactive substance or preparation used   more »

Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis (MAESTRO-03) This study is currently recruiting participants. Verified by BioMS Technology Corp., June 2008   more »

BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and European study of Dirucotide (MBP8298) in patients with secondary progressive MS. The interim analysis included   more »

A drug that Novartis AG is currently testing, in people with Multiple Sclerosis; also has the potential to treat certain viral infections, perhaps including the AIDS virus, U.S. researchers said. Low doses of the drug FTY720, also called Fingolimod, given to mice once   more »

BioMS Medical Corp. announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, and   more »

Therapeutics, Inc. (NASDAQ:OPXA), a company leading in the development of cell therapies for multiple sclerosis (MS) and diabetes, has completed an internal assessment of data from its Phase I/II two year extension study with Tovaxin in patients   more »